Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1BΒ and TSLC1 in neuroblastoma

Oncogene

Volumn 29, Issue 18, 2010, Pages 2681-2690

  Ochiai, H ^a,b   Takenobu, H ^a   Nakagawa, A ^c   Yamaguchi, Y ^a   Kimura, M ^a   Ohira, M ^a   Okimoto, Y ^d   Fujimura, Y ^e   Koseki, H ^e   Kohno, Y ^b   Nakagawara, A ^a   Kamijo, T ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d CHIBA CHILDREN'S HOSPITAL   (Japan)

^e RIKEN Center for Integrative Medical Sciences   (Japan)

Author keywords

Bmi1; KIF1B ; MYCN; Neuroblastoma; TSLC1

Indexed keywords

BMI1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; NEURITE PROMOTING FACTOR;

ARTICLE; BINDING SITE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME; DNA METHYLATION; DNA MICROARRAY; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIF1BBETA GENE; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; TSLC1 GENE; UPREGULATION;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOGLOBULINS; KINESIN; MEMBRANE PROTEINS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 77952240403     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.22     Document Type: Article

References (46)

1. Ando K, Ohira M, Ozaki T, Nakagawa A, Akazawa K, Suenaga Y et al. (2008). Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation. Int J Cancer 123: 2087-2094.
2. Atsuta T, Fujimura S, Moriya H, Vidal M, Akasaka T, Koseki H. (2001). Production of monoclonal antibodies against mammalian Ring1B proteins. Hybridoma 20: 43-46.
3. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. (1984). Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124.
4. Bruggeman SW, Hulsman D, Tanger E, Buckle T, Blom M, Zevenhoven J et al. (2007). Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 12: 328-341.
5. Cao R, Tsukada Y, Zhang Y. (2005). Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 20: 845-854.
6. Caron H. (1995). Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 24: 215-221.
7. Caren H, Ejeskar K, Fransson S, Hesson L, Latif F, Sjoberg RM et al. (2005). A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation. Mol Cancer 4: 10.
8. Cui H, Ma J, Ding J, Li T, Alam G, Ding HF. (2006). Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblas-toma cells in a concentration-dependent manner. J Biol Chem 281: 34696-34704.
9. Cui H, Hu B, Li T, Ma J, Alam G, Gunning WT et al. (2007). Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 170: 1370-1378.
10. Easton J, Wei T, Lahti JM, Kidd VJ. (1998). Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res 58: 2624-2632.
11. Esteller M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
12. Fujimura Y, Isono K, Vidal M, Endoh M, Kajita H, Mizutani-Koseki Y et al. (2006). Distinct roles of Polycomb group gene products in transcriptionally repressed and active domains of Hoxb8. Development 133: 2371-2381.
13. Guney I, Wu S, Sedivy JM. (2006). Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). Proc Natl Acad Sci USA 103: 3645-3650.
14. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
15. Iwama A, Oguro H, Negishi M, Kato Y, Morita Y, Tsukui H et al. (2004). Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 21: 843-851.
16. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. (1999). The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164-168.
17. Jones PA, Baylin SB. (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
18. Kamminga LM, Bystrykh LV, de Boer A, Houwer S, Douma J, Weersing E et al. (2005). The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107: 2170-2179.
19. Kamminga LM, de Haan G. (2006). Cellular memory and hemato-poietic stem cell aging. Stem Cells 24: 1143-1149.
20. Kramps C, Strieder V, Sapetschnig A, Suske G, Lutz W. (2004). E2F and Sp1/Sp3 synergize but are not sufficient to activate the MYCN gene in neuroblastomas. J Biol Chem 279: 5110-5117.
21. Kurata K, Yanagisawa R, Ohira M, Kitagawa M, Nakagawara A, Kamijo T. (2008). Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuro-blastoma cells. Oncogene 27: 741-754.
22. Lessard J, Sauvageau G. (2003). Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255-260.
23. Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P et al. (2004). Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428: 337-341.
24. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. (1996). Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13: 803-812.
25. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. (2003). Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425: 962-967.
26. Molofsky AV, Slutsky SG, Joseph NM, He S, Pardal R, Krishna-murthy J et al. (2006). Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 443: 448-452.
27. Munirajan AK, Ando K, Mukai A, Takahashi M, Suenaga Y, Ohira M et al. (2008). KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death. J Biol Chem 283: 24426-24434.
28. Murakami Y. (2005). Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci 96: 543-552.
29. Nowak K, Kerl K, Fehr D, Kramps C, Gessner C, Killmer K et al. (2006). BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 34: 1745-1754.
30. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A et al. (2005). Expression profiling using a tumor-specific cDNA micro-array predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 7: 337-350.
31. Orlando V, Strutt H, Paro R. (1997). Analysis of chromatin structure by in vivo formaldehyde cross-linking. Methods 11: 205-214.
32. Pietersen AM, van Lohuizen M. (2008). Stem cell regulation by polycomb repressors: postponing commitment. Curr Opin Cell Biol 20: 201-207.
33. Rajasekhar VK, Begemann M. (2007). Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells 25: 2498-2510.
34. Schwartz YB, Pirrotta V. (2008). Polycomb complexes and epigenetic states. Curr Opin Cell Biol 20: 266-273.
35. Sherr CJ. (2004). Principles of tumor suppression. Cell 116: 235-246.
36. Sparmann A, van Lohuizen M. (2006). Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6: 846-856.
37. Strieder V, Lutz W. (2003). E2F proteins regulate MYCN expression in neuroblastomas. J Biol Chem 278: 2983-2989.
38. Sugino Y, Misawa A, Inoue J, Kitagawa M, Hosoi H, Sugimoto T et al. (2007). Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas. Oncogene 26: 7401-7413.
39. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al. (2000). Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6: 529-535.
40. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. (2004). Stem cells and cancer; the polycomb connection. Cell 118: 409-418.
41. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. (2006). The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874.
42. Westemann F, Schwab M. (2002). Genetic parameters of neuroblas-tomas. Cancer Lett 184: 127-147.
43. Yan P, Muhlethaler A, Bourloud KB, Beck MN, Gross N. (2003). Hypermethylation-mediated regulation of CD44 gene expression in human neuroblastoma. Gene Chromosomes Cancer 36: 129-138.
44. Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR et al. (2004). Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 10: 8493-8500.
45. Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J et al. (2003). Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 63: 6299-6310.
46. Yang J, Chai L, Liu F, Fink LM, Lin P, Silberstein LE et al. (2007). Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci USA 104: 10494-10499.